Wild type transthyretin cardiac amyloidosis (wtATTR) and heart failure with reduced ejection fraction (HFrEF): can angiotensin receptor/neprilysin inhibitors be a therapeutic option?
22 May 2023 (11:09 - 11:18)
Organised by: 
Slides
About the speaker
University of Milan-Bicocca, Monza (Italy)
3 More presentations in this session
Doctor A. Diaz Exposito (Malaga, ES)
Doctor S. Vila-Sanjuan (Barcelona, ES)
Doctor P. Suwalski (Berlin, DE)
Access the full session
The Event
Heart Failure 2023
22 May 2023
11:09 CET
You may be interested in
Congress Session
Congress Presentation
Congress Session
